Day One Biopharmaceuticals (DAWN) Corporate presentation summary

Company overview and mission

• Commercial-stage biopharmaceutical company focused on targeted therapies for life-threatening diseases in patients of all ages.

• Founded in 2018, IPO in 2021, and achieved first product approval (OJEMDA) in April 2024.

• Mission centers on addressing urgent needs in pediatric and adult populations with high unmet medical needs.

Key products and pipeline

• OJEMDA (tovorafenib) approved for relapsed/refractory pediatric low-grade glioma (pLGG) with BRAF alterations; positioned as 2L standard of care.

• Pipeline includes FIREFLY-2 (frontline pLGG, pivotal Phase 3), Emi-Le (B7-H4 ADC for ACC), and DAY301 (PTK7 ADC for solid tumors).

• Anticipated milestones: FIREFLY-2 enrollment completion 1H 2026, Emi-Le Phase 1 data mid-2026, DAY301 Phase 1a data 2H 2026.

Market opportunity and growth

• U.S. revenue opportunity exceeds $1B across three high unmet need indications: OJEMDA in r/r and 1L pLGG, and Emi-Le in ACC.

• OJEMDA expansion into frontline pLGG could double its market opportunity.

• Global commercial expansion planned through partnership with Ipsen.